Fig. 4
From: Multi-pathway targeted therapy of MASH-HCC using miR-22
miR-22 prevents liver oncogenesis. A A schematic illustration of the study design, B liver-to-bodyweight (L/B) ratio, spleen-to-bodyweight ratio, C representative liver morphology, H&E-stained liver sections, and Sirus red-stained liver sections. D hepatic mRNA levels of Afp, Ccna2, Gpc3, and Lgals1. E Kaplan–Meier survival curves of overall survival of the studied groups (n = 12–39 mice/group). Data represent mean ± SD (n = 6–8/group). p < 0.05, ∗ p < 0.01, ∗ ∗ p < 0.001 by one-way ANOVA